Compugen Ltd (CGEN) Stock Price

CGENStock

$2.87+78.62%52W

Market Cap$271.86M

P/E6.45x

PEG Ratio1.29

Div yield—

Beta2.77

CGEN Share Price Chart

Favorite Metrics

Price vs S&P 500 (26W)41.11%

Price vs S&P 500 (4W)11.55%

PEG Ratio1.29

VGM Score75.42

P/E Ratio (Annual)6.45x

P/CF (Annual)7.20x

Book Value / Share (Quarterly)$1.01

P/TBV (Annual)0.73x

Indicated Dividend (Annual)$0.00

Revenue Growth (3Y)113.28%

Cash Flow / Share (Quarterly)$0.33

Price vs S&P 500 (YTD)57.32%

Gross Margin (TTM)87.00%

Net Profit Margin (TTM)-420.79%

EPS (TTM)$0.36

10-Day Avg Trading Volume0.34M

EPS Excl Extra (TTM)$0.36

Revenue Growth (5Y)105.20%

EPS (Annual)$0.38

ROI (Annual)34.40%

Gross Margin (Annual)94.01%

Net Profit Margin (5Y Avg)-443.04%

Cash / Share (Quarterly)$1.43

P/E Basic Excl Extra (TTM)6.54x

Revenue Growth QoQ (YoY)4480.41%

P/E Normalized (Annual)6.45x

ROA (Last FY)22.57%

Revenue Growth TTM (YoY)161.14%

EBITD / Share (TTM)$-0.40

ROE (5Y Avg)-41.50%

Operating Margin (TTM)-460.07%

Cash Flow / Share (Annual)$0.33

P/B Ratio2.39x

P/B Ratio (Quarterly)2.11x

Net Income / Employee (Annual)$666,800

EV / Revenue (TTM)2.87x

Net Interest Coverage (TTM)0.50x

ROA (TTM)27.51%

EV / EBITDA (TTM)8.01x

EPS Incl Extra (Annual)$0.38

Current Ratio (Annual)6.56x

Quick Ratio (Quarterly)6.23x

3-Month Avg Trading Volume0.41M

52-Week Price Return78.62%

EV / Free Cash Flow (Annual)6.88x

P/E Incl Extra (TTM)6.54x

Revenue / Employee (TTM)$108,695,600,000

Tangible BV / Share (Quarterly)$0.60

P/S Ratio (Annual)6.81x

Asset Turnover (Annual)0.28x

52-Week High$3.23

Operating Margin (5Y Avg)-462.61%

EPS Excl Extra (Annual)$0.38

CapEx CAGR (5Y)4.81%

Tangible BV CAGR (5Y)21.53%

26-Week Price Return52.35%

Quick Ratio (Annual)6.47x

13-Week Price Return-0.77%

Total Debt / Equity (Annual)0.00x

Current Ratio (Quarterly)6.23x

Enterprise Value$215.44M

Revenue / Share Growth (5Y)98.61%

Asset Turnover (TTM)0.09x

Book Value / Share Growth (5Y)9.44%

Revenue / Employee (Annual)$631,300

Inventory Turnover (Annual)28.20x

Pretax Margin (Annual)-29.24%

Cash / Share (Annual)$1.54

3-Month Return Std Dev55.68%

Gross Margin (5Y Avg)91.74%

Net Income / Employee (TTM)$657,600

ROE (Last FY)34.40%

Net Interest Coverage (Annual)11.00x

EPS Basic Excl Extra (Annual)$0.38

P/FCF (TTM)5.28x

Receivables Turnover (TTM)2.68x

EV / Free Cash Flow (TTM)6.88x

Total Debt / Equity (Quarterly)0.00x

EPS Incl Extra (TTM)$0.36

Receivables Turnover (Annual)29.70x

ROI (TTM)47.72%

P/S Ratio (TTM)7.53x

Pretax Margin (5Y Avg)-445.03%

Revenue / Share (Annual)$0.38

Tangible BV / Share (Annual)$0.90

Price vs S&P 500 (52W)60.31%

P/E Ratio (TTM)6.54x

EPS Growth TTM (YoY)20.54%

Year-to-Date Return69.28%

5-Day Price Return8.82%

EPS Normalized (Annual)$0.38

ROA (5Y Avg)-33.24%

Net Profit Margin (Annual)-56.05%

Month-to-Date Return10.21%

EBITD / Share (Annual)$0.34

Operating Margin (Annual)-38.83%

P/CF (TTM)7.20x

ROI (5Y Avg)-37.79%

P/E Excl Extra (TTM)6.54x

LT Debt / Equity (Quarterly)0.03x

EPS Basic Excl Extra (TTM)$0.36

P/TBV (Quarterly)1.06x

P/B Ratio (Annual)1.39x

Inventory Turnover (TTM)24.20x

Pretax Margin (TTM)-420.49%

Book Value / Share (Annual)$1.09

Price vs S&P 500 (13W)-3.56%

Beta2.77x

P/FCF (Annual)7.27x

Revenue / Share (TTM)$0.09

ROE (TTM)47.72%

52-Week Low$1.29

vGradeB

gGradeA

mGradeB

vgmGradeB

CGEN Earnings Surprise History

Q2 25-0.08est. -0.09

Q3 25-0.07est. -0.09

Q4 250.60est. 0.14

Q1 26-0.08est. -0.08

Q2 26-0.07est. -0.09

CGEN Analyst Recommendations

May 2026

Jun 2026

Jul 2026

Aug 2026

4.33

4.36

Industry Peers — Biological Products(183)

Symbol	Value Score	Growth Score	Momentum Score	Price
CGENCompugen Ltd	B	A	B	$2.87
AMGNAmgen Inc	C	C	B	$442.24
GILDGilead Sciences Inc	C	B	B	$148.77
MRNAModerna, Inc. Common Stock	D	C	A	$158.83
ARGXargenx SE American Depositary Shares	D	A	B	$1019.49
RVMDRevolution Medicines, Inc. Common Stock	F	—	A	$211.38
BIIBBiogen Inc. Common Stock	C	D	B	$220.77
BNTXBioNTech SE American Depositary Share	C	C	B	$114.05
NBIXNeurocrine Biosciences Inc	C	B	C	$153.37
EXELExelixis Inc	C	B	B	$56.72
HALOHalozyme Therapeutics, Inc.	C	B	A	$109.32
TECHBio-Techne Corp.	D	C	B	$72.33
KRYSKrystal Biotech, Inc. Common Stock	D	B	B	$356.19
KYMRKymera Therapeutics, Inc. Common Stock	D	B	B	$126.64
RGENRepligen Corp	D	C	A	$181.69
APGEApogee Therapeutics, Inc. Common Stock	—	—	A	$134.85
TWSTTwist Bioscience Corporation Common Stock	D	B	A	$151.42
PCVXVaxcyte, Inc. Common Stock	—	—	B	$61.09
QGENQIAGEN N.V.	C	C	C	$43.65
IMVTImmunovant, Inc. Common Stock	—	—	B	$43.50
IBRXImmunityBio, Inc. Common Stock	F	A	C	$8.19
SRRKScholar Rock Holding Corporation Common Stock	F	—	B	$58.25
CGONCG Oncology, Inc. Common stock	F	A	A	$78.95
CRSPCRISPR Therapeutics AG	D	B	B	$60.90
RLAYRelay Therapeutics, Inc. Common Stock	F	D	A	$20.57
ADPTAdaptive Biotechnologies Corporation Common Stock	D	B	A	$26.25
DNLIDenali Therapeutics Inc. Common Stock	F	—	B	$24.93
IOVAIovance Biotherapeutics, Inc. Common Stock	C	B	A	$8.44
BEAMBeam Therapeutics Inc. Common Stock	C	B	B	$31.03
TARSTarsus Pharmaceuticals, Inc. Common Stock	D	A	B	$71.45
BCRXBioCryst Pharmaceuticals Inc	B	A	B	$9.83
KODKodiak Sciences Inc Common Stock	—	—	B	$39.46
COAGHemab Therapeutics Holdings, Inc. Common Stock	—	—	B	$49.65
MESOMesoblast Limited American Depositary Shares	D	B	C	$17.19
VCELVericel Corporation	D	B	C	$43.22
ADMAADMA Biologics, Inc.	C	C	C	$9.72
TSHATaysha Gene Therapies, Inc. Common Stock	F	B	B	$6.20
IMCRImmunocore Holdings plc American Depositary Shares	D	B	B	$37.40
RXRXRecursion Pharmaceuticals, Inc. Class A Common Stock	D	C	C	$3.56
VIRVir Biotechnology, Inc. Common Stock	B	B	B	$10.71
INBXInhibrx Biosciences, Inc. Common Stock	D	C	B	$122.72
ALVOAlvotech Ordinary Shares	C	D	B	$5.05
MAZEMaze Therapeutics, Inc. Common Stock	—	—	B	$30.42
NVAXNovavax Inc	B	D	C	$9.44
REPLReplimune Group, Inc.	—	—	A	$15.80
SLBTSL Science Holding Limited Ordinary Shares	—	—	F	$2.64
MGTXMeiraGTx Holdings plc Ordinary Shares	D	C	A	$14.92
VORVor Biopharma Inc. Common Stock	—	—	B	$24.01
CGEMCullinan Therapeutics, Inc. Common Stock	—	—	A	$22.95
IMTXImmatics N.V. Ordinary Shares	C	D	C	$9.24
ODTXOdyssey Therapeutics, Inc. Common Stock	—	C	A	$26.23

About Compugen Ltd

Compugen Ltd is a clinical-stage biopharmaceutical company developing cancer immunotherapies using computational drug discovery to identify novel immune targets. The company has four programs in clinical development targeting immune checkpoints and resistance pathways, including COM701, COM902, and bapotulimab, plus early-stage programs focusing on myeloid targets.